Mechanisms of *Francisella tularensis* Intracellular Pathogenesis

Jean Celli¹ and Thomas C. Zahrt²

¹Laboratory of Intracellular Parasites, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana 59840

²Department of Microbiology and Molecular Genetics, Center for Infectious Disease Research, Medical College of Wisconsin, Milwaukee, Wisconsin 53226

Correspondence: tzahrt@mcw.edu

Francisella tularensis is a zoonotic intracellular pathogen and the causative agent of the debilitating febrile illness tularemia. Although natural infections by *F. tularensis* are sporadic and generally localized, the low infectious dose, with the ability to be transmitted to humans via multiple routes and the potential to cause life-threatening infections, has led to concerns that this bacterium could be used as an agent of bioterror and released intentionally into the environment. Recent studies of *F. tularensis* and other closely related *Francisella* species have greatly increased our understanding of mechanisms used by this organism to infect and cause disease within the host. Here, we review the intracellular life cycle of *Francisella* and highlight key genetic determinants and/or pathways that contribute to the survival and proliferation of this bacterium within host cells.

Francisella are nonmotile, encapsulated, Gram-negative coccobacilli and are facultative intracellular pathogens of humans and many animals. The genus consists of three recognized species: *Francisella tularensis*, *Francisella novicida*, and *Francisella philomiragia*. *F. tularensis* is highly infectious and causes a potentially debilitating febrile illness known as tularemia. *F. novicida* and *F. philomiragia* are rarely pathogenic in man and usually only in individuals who are severely immunocompromised. Although *F. novicida* has a limited ability to cause disease in humans, this organism continues to serve as an important surrogate model to study aspects of *F. tularensis* pathogenesis and host response to infection owing to its reduced biosafety require-

ments, the conserved nature of its genome relative to pathogenic *F. tularensis* derivatives, its apparently similar intracellular life cycle, and its ability to cause a tularemia-like disease in in vivo model systems of infection.

F. tularensis is transmitted from infected animals to humans by multiple routes and can cause disease of varying severities depending on the portal of entry, infectious dose, and subspecies (biovar) of the infecting strain. Person-to-person transmission of *F. tularensis* has not yet been reported. *F. tularensis* subspecies *tularensis* is the most infectious biovar ($ID_{50} < 10$ cfu) and is responsible for most cases of tularemia in North America (Saslaw et al. 1961a). This subspecies causes the most severe disease symptoms

Editors: Pascale Cossart and Stanley Maloy

Additional Perspectives on Bacterial Pathogenesis available at www.perspectivesinmedicine.org

Copyright © 2013 Cold Spring Harbor Laboratory Press; all rights reserved; doi: 10.1101/cshperspect.a010314

Cite this article as *Cold Spring Harb Perspect Med* 2013;3:a010314

J. Celli and T.C. Zahrt

and has mortality rates approaching 60% if untreated (Saslaw et al. 1961a,b; Dienst 1963). Type A strain Schu S4 is the most commonly studied isolate from this subspecies. *F. tularensis* subspecies *holarctica* has an infectious dose $<10^3$ cfu and is the primary cause of tularemia in Europe and other regions in the Northern Hemisphere. Infections by this subspecies are generally associated with milder disease symptoms and are rarely fatal. The live vaccine strain (LVS) is an attenuated isolate derived from this subspecies and was developed in the former Soviet Union. However, it is not licensed for use in the United States. The remaining biovar, *F. tularensis* subspecies *mediastica*, only occasionally causes disease in humans.

Infection by *F. tularensis* occurs primarily after inadvertent exposure to infected wildlife species, most frequently rodents, hares, and rabbits. Transmission to humans occurs via direct contact, through arthropod or insect vectors, by ingestion of contaminated material(s), or by inhalation of aerosolized organisms. Regardless of the entry route, *F. tularensis* can disseminate from the initial infection site to the lungs where it can cause respiratory tularemia, the most severe form of the disease. The low infectious dose, with the ability to be transmitted to humans via multiple routes, and potential to cause life-threatening illness has resulted in the designation of *F. tularensis* by the United States Centers for Infectious Disease Control and Prevention as a Category A Select Agent with potential to be weaponized and/or intentionally released into the environment. These characteristics have resulted in a renewed interest in the study of *Francisella*, including characterization of the *F. tularensis* life cycle, and identification of bacterial and/or host determinants important for aspects of its pathogenesis.

OVERVIEW OF THE *Francisella* LIFE CYCLE

Although *Francisella* shows an extracellular phase during bacteremia in mice (Forestal et al. 2007), survival and replication within host cells is thought to be a key aspect of its life cycle. This is exemplified by the ability of various strains of *F. tularensis* subsp. *tularensis* and *ho-*

larctica and of *F. novicida* to enter, survive, and proliferate within a variety of host-cell types, including macrophages, dendritic cells, polymorphonuclear neutrophils, hepatocytes, endothelial, and type II alveolar lung epithelial cells (Oyston et al. 2004; McCaffrey and Allen 2006; Hall et al. 2007, 2008). Because intracellular proliferation is essential to *Francisella* virulence, much research has focused on understanding and characterizing specific steps in the intracellular cycle of this bacterium. It has become clear that *Francisella* survival and proliferation strategies rely on physical escape from its original phagosome and replication in the host-cell cytosol (Fig. 1), making this bacterium a typical cytosol-dwelling pathogen.

Francisella ENTRY INTO MAMMALIAN CELLS

Although entry into nonphagocytic cells remains to be further defined, phagocytosis of *Francisella* by macrophages has been extensively studied and involves the engagement of different phagocytic receptors depending on the bacterium's opsonization conditions. The mannose receptor (MR) plays a significant role in nonopsonic uptake of *F. novicida* and *F. tularensis* strains by either human monocyte-derived macrophages (MDMs), murine bone marrow-derived macrophages (BMMs), or J774A.1 macrophage-like cells (Balagopal et al. 2006; Schulert and Allen 2006; Geier and Celli 2011). Additionally, yet-to-be-identified receptors are also likely engaged by nonopsonized *Francisella*. Serum opsonization, which markedly enhances *Francisella* uptake (Clemens et al. 2004, 2005; Balagopal et al. 2006; Schulert and Allen 2006; Geier and Celli 2011), mostly redirects the bacterium to the complement receptor CR3 in human and murine macrophages, human neutrophils, and dendritic cells (Balagopal et al. 2006; Ben Nasr et al. 2006; Schulert and Allen 2006; Barker et al. 2009a). The scavenger receptor A (SR-A) (Pierini 2006; Geier and Celli 2011), Fcγ receptors (Balagopal et al. 2006), nucleolin (Barel et al. 2008), and the lung surfactant protein A (SP-A) (Balagopal et al. 2006) have also been implicated to various degrees in uptake of serum-opsonized *Francisella* by murine or human macrophages.

Figure 1. Model of the *Francisella* intracellular cycle depicting stages that are common to murine and human phagocytes. Upon phagocytosis, bacteria reside in an early phagosome (FCP) that interacts with early (EE) and late (LE) endocytic compartments but not lysosomes (Lys). Bacteria rapidly disrupt the FCP membrane and reach the cytosol where they undergo extensive replication, a process followed by cell death, bacterial release, and subsequent infection.

Conversely, Fcγ receptors are the main phagocytic receptors engaged during uptake of antibody-opsonized *Francisella*, which is also enhanced compared with nonopsonic conditions (Balagopal et al. 2006; Geier and Celli 2011). Opsonophagocytosis of microbes is generally associated with enhanced uptake, as is the case for *Francisella*. This suggests that this pathogen exposes a limited number of ligands to nonopsonic phagocytic receptors, possibly providing the bacterium with means to limit uptake by bactericidal phagocytes. Additionally, such bacterial ligands may engage receptors that trigger less bactericidal pathways, thereby ensuring better intracellular survival. Consistent with this hypothesis, intracellular proliferation of nonopsonic SchuS4 in murine BMMs is superior to that of opsonized bacteria (Geier and Celli 2011).

THE *Francisella*-CONTAINING PHAGOSOME

Following uptake, *Francisella* resides within a phagosome, the *Francisella*-containing phago-

some (FCP), an initial vacuolar compartment along the endocytic degradative pathway that is normally subjected to progressive maturation into a bactericidal phagolysosome. Newly formed FCPs sequentially acquire markers of early endosomes and late endosomes, such as EEA-1, CD63, LAMP-1, LAMP-2, and Rab7 (Clemens et al. 2004, 2009; Santic et al. 2005a, 2008; Checroun et al. 2006; Chong et al. 2008; Wehrly et al. 2009), indicative of a normal maturation process. Yet, such interactions do not proceed toward fusion with lysosomes, as FCPs do not seem to accumulate lysosomal luminal hydrolases, such as cathepsin D, or lysosomal tracers (Anthony et al. 1991; Clemens et al. 2004; Santic et al. 2005b; Bonquist et al. 2008) and bacteria physically disrupt the phagosomal membrane and escape into the host-cell cytosol (see below). Another important feature of phagosomal maturation is the progressive acidification of the phagosomal lumen, via the recruitment of the vacuolar ATPase (v-ATPase), which is both a requirement and a consequence

J. Celli and T.C. Zahrt

of phagosomal maturation (Huynh and Grinstein 2007). Whether the FCP becomes acidified or not before disruption remains contentious. Some studies have shown that FCPs containing either LVS, Schu S4, or a *F. tularensis* clinical isolate resist acidification and acquire limited amounts of v-ATPase (Clemens et al. 2004; Bonquist et al. 2008; Cremer et al. 2009), whereas others report that FCPs containing either *F. novicida* strain U112 or SchuS4 become acidified and acquire the v-ATPase proton pump before phagosomal disruption (Chong et al. 2008; Santic et al. 2008). Additional controversy resides in the fact that studies that found that FCPs become acidified show a role for acidification in optimal phagosomal escape (Chong et al. 2008; Santic et al. 2008), whereas a study in which FCPs were found to resist acidification did not observe any effect of acidification inhibitors (Clemens et al. 2009). It is noteworthy that acidified FCPs are observed using nonopsonic infection conditions, whereas nonacidified FCPs are generated using serum-opsonized *Francisella*, suggesting that the mode of uptake may affect acidification of the FCP and account for discrepancy in the literature. Although FCP intraluminal pH remains to be measured under different opsonization conditions, these studies nonetheless suggest that physicochemical cues within the FCP contribute to *Francisella* intracellular fate. This reinforces the importance of the FCP in the *Francisella* intracellular cycle, in agreement with the fact that it constitutes the site of intracellular induction of virulence genes encoded within the *Francisella* pathogenicity island (FPI), a genetic loci that has been predicted to encode a type VI secretion system (Nano et al. 2004; Chong et al. 2008; Wehrly et al. 2009).

REACTIVE OXYGEN SPECIES AND INHIBITION OF NADPH OXIDASE ACTIVATION

A major bactericidal function of phagosomes is production of reactive oxygen species (ROS) during the oxidative burst, a process mediated by recruitment and assembly of a multiprotein complex called the NADPH oxidase onto the

phagosomal membrane. This enzyme mediates the conversion of molecular oxygen to superoxide (O_2^-) anions, an ROS that can be subsequently converted to other reactive species including hydrogen peroxide (H_2O_2), hypochlorous acid (bleach), and peroxynitrite ($ONOO^-$) within certain cell types or under certain conditions (Zahrt and Deretic 2002). The NADPH oxidase complex consists of two integral membrane proteins ($gp91^{phox}$ and $p22^{phox}$) that together form flavocytochrome b_{558} , and various soluble components that are translocated to the phagosomal membrane on activation. Flavocytochrome b_{558} contains the redox center of NADPH oxidase and is the docking site for cytosolic subunits of the enzyme complex including $p47^{phox}$, $p40^{phox}$, and $p67^{phox}$. Translocation of these determinants to flavocytochrome b_{558} requires phosphorylation of $p47^{phox}$ and $p40^{phox}$; activation of NADPH oxidase also requires association with a small G protein such as Rac1 or Rac2 (Babior 2004).

To ensure their survival, many bacterial pathogens have evolved strategies to resist and/or interfere with ROS generation. For *Francisella*, these survival strategies have been best elucidated in human polymorphonuclear neutrophils (PMNs) (McCaffrey and Allen 2006; Allen and McCaffrey 2007; Buchan et al. 2009; Schullert et al. 2009; McCaffrey et al. 2010; Mohapatra et al. 2010), a cell type normally encountered by the bacterium in vivo and a potent producer of NADPH oxidase-generated O_2^- (Allen and McCaffrey 2007). In these cells, *F. tularensis* and *F. novicida* have been shown to actively disrupt ROS generation by altering at least two different steps in NADPH oxidase activation: (1) by inhibiting assembly of flavocytochrome b_{558} in the phagosomal membrane (McCaffrey et al. 2010), and/or (2) by inhibiting the phosphorylation of $p47^{phox}$ and $p40^{phox}$ (McCaffrey et al. 2010; Mohapatra et al. 2010). Inhibition of NADPH oxidase assembly by *F. tularensis* is dependent on opsonization, and is observed with strains from both *F. tularensis* subspecies *tularensis* and *holarctica*, including the LVS (McCaffrey et al. 2010; Geier and Celli 2011). Interestingly, *F. tularensis* also possesses the unique ability to inhibit NADPH oxidase

activity postcomplex assembly, an event that limits subsequent PMN activation by other stimuli and diminishes ROS production following phagocytosis of antibody-opsonized *F. tularensis* (McCaffrey et al. 2010). Regardless of mechanism(s), inhibition of NADPH oxidase activity enhances survival of both *F. tularensis* and *F. novicida* in this cell type (McCaffrey and Allen 2006; McCaffrey et al. 2010; Mohapatra et al. 2010; Geier and Celli 2011). Similarly, monocytes or MDMs that have been infected with *F. tularensis* or *F. novicida* also fail to trigger a robust and/or productive oxidative burst (Schulert et al. 2009; Mohapatra et al. 2010; Geier and Celli 2011). However, in contrast to PMNs, the inability of monocytes and MDMs to produce ROS following infection is likely owing to *Francisella* engagement of and/or internalization by receptors not coupled to NADPH oxidase activation (Schulert et al. 2009). Consistent with this observation, intracellular growth of *F. tularensis* or *F. novicida* is similar following ex vivo infection of monocytes and/or MDMs from wild-type mice compared with $p47^{phox-/-}$ mice (Lindgren et al. 2005; Mohapatra et al. 2010). Furthermore, IgG-opsonization of *F. tularensis* results in NADPH oxidase-dependent ROS generation in wild-type murine BMMs, an affect that is not observed in macrophages lacking $gp91^{phox}$ (Geier and Celli 2011).

Although the ability of *Francisella* to inhibit NADPH oxidase activity in neutrophils in vitro has been well established, the importance of neutrophils and/or NADPH oxidase activity in this and other cell types in vivo remains less clear. Antibody-mediated depletion of neutrophils from mice, or targeted recruitment of neutrophils to the lungs using intranasally delivered recombinant MIP-2, a neutrophil-chemotactic chemokine, does not affect bacterial burden or time-to-death kinetics in mice that have been infected with *F. tularensis* compared with untreated control animals (KuoLee et al. 2011). Similarly, $gp91^{phox-/-}$ mice show only slight differences in time-to-death and overall bacterial burden in target organs of infection compared with wild-type animals following respiratory infection with *F. tularensis* (KuoLee et al.

2011). Thus, although *Francisella* may possess specific strategies to inhibit, counteract, or bypass the production of ROS by neutrophils and other phagocytes, the importance of the NADPH oxidase in controlling infection by pathogenic biovars of *Francisella* appears limited in murine tularemia.

Several bacterial determinants have been implicated in the resistance of *Francisella* to ROS. For example, *Francisella* encodes a number of putative acid phosphatases, enzymes that hydrolyze monoesters at acidic pH, that may inhibit the respiratory burst. Purified AcpA, the major contributor of acid phosphatase activity in *Francisella*, is able to inhibit the oxidative burst in porcine neutrophils that have been activated with exogenous stimulants (Reilly et al. 1996). Recent evidence suggests that AcpA is secreted by *F. tularensis* and *F. novicida* strains in vitro (Dai et al. 2011), and is detectable in the cytosol of macrophages infected with *F. novicida* shortly after infection (Dai et al. 2011). These findings indicate that AcpA would be in a physical location (near the phagosomal membrane or in the cytosol) to interact with membrane-bound or soluble components of the NADPH oxidase (Dai et al. 2011). Consistent with these observations, an *F. novicida* mutant lacking AcpA is partially compromised in its ability to suppress the oxidative burst following infection of human neutrophils or MDMs (Mohapatra et al. 2010), a phenotype that becomes more pronounced as additional predicted acid phosphatases (*acpB*, *acpC*, and *hap*) are deleted from the bacterium (Mohapatra et al. 2010). Furthermore, loss of AcpA and/or other acid phosphatases reduces the ability of *F. novicida* to survive following infection of these and other cell types in vitro (Mohapatra et al. 2007, 2008, 2010), and in vivo following intraperitoneal or intranasal infection of mice (Mohapatra et al. 2007, 2008). The importance of acid phosphatases in resistance of *F. novicida* to ROS can also be seen following treatment of neutrophils and MDMs with reagents that block assembly and/or function of NADPH oxidase, or in macrophages from $p47^{phox-/-}$ mice, where the ability of *F. novicida* $\Delta acpA$ and/or $\Delta acpABCH$ mutants to survive intracellularly is

J. Celli and T.C. Zahrt

improved (Mohapatra et al. 2010). Additionally, ascorbate treatment of murine or human macrophages infected with the LVS blocks acid phosphatase production and inhibits intracellular growth of the bacterium, a phenotype that is dependent on production of AcpA (McRae et al. 2009). Thus, AcpA and other predicted acid phosphatases appear to play an important role in NADPH oxidase inhibition and resistance to ROS following infection by *F. novicida*.

It is, however, important to note that AcpA and/or the other acid phosphatases appear to play little if any role in the inhibition of NADPH oxidase activity or resistance to ROS in phagocytes that have been infected with human-virulent strains of *F. tularensis*. An *acpA* mutant generated in Schu S4 does not trigger a respiratory burst and shows similar growth characteristics to the wild-type parent following infection of human PMNs, even though this bacterium lacks detectable acid phosphatase activity (McCaffrey et al. 2010). Similarly, deletion of *acpA*, *acpB*, or *acpC* alone or sequentially does not alter growth and/or trafficking characteristics of Schu S4 in vitro in murine BMMs or human MDMs, or in vivo following intranasal infection of mice (Child et al. 2010). Thus, acid phosphatases may play a different role in *F. novicida* compared with *F. tularensis*, or strains of *Francisella* that are pathogens of humans may possess/use additional determinants/strategies for ROS resistance that are not conserved or functional in *F. novicida*.

Apart from acid phosphatases, other determinants have also been implicated in *Francisella* resistance to ROS. A number of determinants involved in pyrimidine biosynthesis (*carA*, *carB*, and *pyrB*) mediate resistance to ROS in *F. tularensis* LVS, although it is unclear whether these genes act indirectly by simply enhancing the fitness of the bacterium (Schulert et al. 2009). FevR, a transcription factor that regulates expression of ~100 genes including those from the FPI (Brotcke and Monack 2008; Meibom et al. 2009), is also required for the inhibition of NADPH oxidase activation and subsequent ROS production in PMNs by both *F. tularensis* LVS (Buchan et al. 2009) and *F. tularensis* subspecies *tularensis* (McCaffrey et al. 2010).

FTN1133 (FTL0803) encodes a hypothetical gene product that is required for resistance of *F. novicida* and *F. tularensis* LVS to organic hydroperoxides (Llewellyn et al. 2011). Mutants lacking this enzyme are attenuated for survival in macrophages in vitro and show reduced burdens in mice following intradermal infection, a phenotype that is partially or completely ablated in cells or animals lacking gp91^{phox} (Llewellyn et al. 2011). *F. tularensis* also encodes at least two superoxide dismutases that mediate the detoxification of superoxide to H₂O₂ and O₂. *sodB*, encoding an FeSOD, and *sodC*, encoding CuZn SOD, mediate resistance to paraquat, H₂O₂, and/or pyrogallol in *F. tularensis* LVS (Bakshi et al. 2006; Melillo et al. 2009), and are required for virulence of *F. tularensis* LVS in macrophages and mice (Bakshi et al. 2006). The attenuation in virulence observed with these strains in vitro and in vivo is attributable to NADPH oxidase, as addition of NADPH oxidase inhibitors or utilization of cells or mice unable to make this enzyme complex fail to control infection (Melillo et al. 2009). Finally, *F. tularensis* LVS mutants lacking KatG, a catalase, show increased sensitivity to H₂O₂ in vitro and are attenuated for virulence in mice in vivo (Lindgren et al. 2007). Interestingly, a similar phenotype is not observed in strains from subspecies *tularensis* (Lindgren et al. 2007). Thus, *Francisella* likely uses multiple strategies and a variety of determinants to mediate resistance to ROS.

Francisella PHAGOSOMAL ESCAPE

Several laboratories have described phagosomal escape by various strains of *F. tularensis* or *F. novicida* in either human or murine macrophages, and other cell types (Golovliov et al. 2003; Clemens et al. 2004; Santic et al. 2005a, 2008; Checroun et al. 2006; Chong et al. 2008), clearly indicating that this process is conserved and is a hallmark of the *Francisella* intracellular life cycle. The study of phagosomal escape kinetics have nonetheless brought controversy to the field, as early studies have reported phagosomal disruption and bacterial access to the cytosol that range anywhere from 1 h to 8 h post-infection (Golovliov et al. 2003; Clemens et al.

2004; Santic et al. 2005a; Checroun et al. 2006; McCaffrey and Allen 2006). Such large variations in kinetics are likely attributed to technical differences in the assays and criteria used to assess phagosomal disruption, and also to variations in the models studied between laboratories where different species and strains of *Francisella*, and different macrophage models were examined. In support of the latter, more recent side-by-side comparisons of phagosomal escape kinetics of *F. tularensis* and *F. novicida* strains have highlighted differences in this process (Chong et al. 2008). For example, more rapid phagosomal escape is observed under nonopsonic conditions (Golovliov et al. 2003; Lindgren et al. 2004; Checroun et al. 2006; Chong et al. 2008; Santic et al. 2008; Barker et al. 2009a; Wehrly et al. 2009; Child et al. 2010; Edwards et al. 2010), whereas slower escape kinetics occur when opsonic conditions are used (Clemens et al. 2004; McCaffrey and Allen 2006; Schulert et al. 2009). Recent systematic comparisons of phagosomal escape kinetics by non-opsonic and opsonized SchuS4 in murine macrophages have clarified this issue further by demonstrating that opsonization of *Francisella* with either complement or antibodies targets bacteria to phagocytic pathways that restrict the extent and timing of phagosomal escape (Geier and Celli 2011). Although the basis for restricted phagosomal escape on serum opsonization is unclear, that occurring on antibody opsonization and bacterial targeting to Fcγ receptors depends on the rapid and transient NADPH oxidase-dependent oxidative burst (Geier and Celli 2011) that the bacteria do not seem to be able to prevent, further confirming that conditions encountered by phagocytosed *Francisella* within the FCP can influence its intracellular fate.

Francisella phagosomal escape is requisite to intracellular proliferation, as exemplified by the inability of numerous phagosomal escape-deficient mutants to grow within macrophages (Lindgren et al. 2004; Santic et al. 2005b; Bonquist et al. 2008; Barker et al. 2009b; Wehrly et al. 2009; Broms et al. 2012). Given the important role of phagosomal escape in the *Francisella* intracellular cycle, much effort has been made to

identify bacterial factors that contribute to this process. Unlike *Listeria monocytogenes* or *Shigella flexneri*, *Francisella* does not encode lipid hydrolases or phospholipases classically involved in phagosomal membrane disruption (Larsson et al. 2005). However, *F. tularensis* does appear to express a type VI-like secretion system (encoded by the FPI) (Nano et al. 2004), and numerous genes that are expressed from this genetic locus or that regulate expression from this locus are important for this phagosomal egress (reviewed in Chong et al. 2008). These include *iglC* and *iglD* (Lindgren et al. 2004; Santic et al. 2005b; Bonquist et al. 2008; Chong et al. 2008), *pdpA* (Schmerk et al. 2009), *iglI* and *iglJ* (Barker et al. 2009b; McCaffrey et al. 2010), *vgrG* (Barker et al. 2009b; Broms et al. 2012), *dotU* (Broms et al. 2012), *mglA* (Baron and Nano 1998; Santic et al. 2005b; Bonquist et al. 2008), *fevR* (Brotcke and Monack 2008; Buchan et al. 2009; Wehrly et al. 2009), and *migR* (Buchan et al. 2009). However, other determinants not linked to the FPI have also been implicated in phagosomal escape by *Francisella* including the acid phosphatases of *F. novicida* (AcpA, AcpB, AcpC, and Hap) (Mohapatra et al. 2008), pyrimidine biosynthetic genes (*carA*, *carB*, and *pyrB*) (Schulert et al. 2009), as well as several genes of unknown function including *FTT1103* (Qin and Mann 2006; Qin et al. 2009) and *FTT1676* (Wehrly et al. 2009). Thus, it remains unclear whether *Francisella* use a single mechanism for escape from the phagosome; further delineation of this process, including the genes required, remains a top priority in the field given its importance for subsequent stages of *Francisella* survival.

Francisella REPLICATION IN THE CYTOSOL

Besides phagosomal escape, the ability of *Francisella* to proliferate within the host-cell cytosol is another key aspect of its intracellular life cycle, as exemplified by the avirulence in mice of the large number of identified replication-deficient mutants (Brotcke et al. 2006; Tempel et al. 2006; Su et al. 2007; Weiss et al. 2007; Alkhuder et al. 2009; Wehrly et al. 2009). Although the cytosol may be viewed as permissive for bacterial

J. Celli and T.C. Zahrt

proliferation, compared with a vacuole along the endocytic degradative pathway, only cytosol-adapted pathogens can readily proliferate within this host-cell compartment (O’Riordan and Portnoy 2002), through the expression of dedicated factors and interactions with host components that either favor or antagonize bacterial growth. Because phagosomal escape is a prerequisite to cytosolic replication, identifying bacterial factors that are specifically required for growth in the cytosol (and not for phagosomal escape) via mutagenesis and in vitro and/or in vivo screens has been difficult. In general, identification of specific *Francisella* cytosolic replication-defective mutants has required use of more specialized secondary readouts including those based on electron and/or immunofluorescence microscopy. To date, only purine biosynthetic genes (*purMCD*) (Pechous et al. 2006, 2008), a γ -glutamyl transpeptidase (*ggt*) (Alkhuder et al. 2009), and several genes of unknown function including *FTT0369c/dipA* (Wehrly et al. 2009; Chong et al. 2012), *FTT0989* (Brotcke et al. 2006), and *ripA* (Fuller et al. 2008), have been identified as being specifically required for cytosolic replication by *Francisella*. However, it is likely that there remain a large number of additional gene products that also contribute to this process (reviewed in Chong et al. 2008).

Although *Francisella* have evolved mechanisms to adapt to a cytosolic lifestyle, some host factors have been identified that either contribute or interfere with cytosolic proliferation. Recently, Akimana et al. have identified through a genome-wide RNAi screen in *Drosophila melanogaster* S2R⁺ cells the type III PI4-kinase α subunit PI4KC and the ubiquitin-specific peptidase USP22 as required for cytosolic replication of *F. novicida* (Akimana et al. 2010). Whether the same host proteins are required for replication of virulent *F. tularensis* and what their function in bacterial replication is remains to be established. Nonetheless, these findings argue that this bacterium modulates specific host pathways associated with lipid signaling and ubiquitin systems to foster replication.

Not surprisingly, innate immune mechanisms have been shown to negatively control

intracellular proliferation of *Francisella*. The cytokine interferon (IFN)- γ is essential to control primary infections (Leiby et al. 1992; Elkins et al. 1996), and has long been known to restrict intracellular growth of various *Francisella* strains in different host-cell models (Anthony et al. 1992; Fortier et al. 1992; Polsinelli et al. 1994), although the effector mechanisms are unclear. IFN- γ control of either LVS or SchuS4 intracellular growth in murine peritoneal exudate cells (PECs) seems to depend on generation of nitric oxide by the inducible nitric oxide synthase (iNOS) (Lindgren et al. 2005, 2007), but not in murine alveolar macrophages (Polsinelli et al. 1994), nor in either human blood-derived or murine bone marrow-derived primary macrophages (Edwards et al. 2010). Nonetheless, independent studies have established that cytosolic replication rather than phagosomal escape of *F. tularensis* is the target of IFN- γ , as this cytokine does not affect phagosomal escape of either LVS or SchuS4 in either J774A.1 cells and human or murine primary macrophages (Bonquist et al. 2008; Edwards et al. 2010), but restricts cytosolic proliferation (Edwards et al. 2010). These findings are, however, inconsistent with those of Santic et al. (2005a), who reported that IFN- γ activation of human blood-derived macrophages prevented phagosomal escape of *F. novicida*. Although variations in the experimental designs of these studies may account for such contrasting conclusions, and further work is required to reconcile these results and clarify the effector mechanisms induced by IFN- γ , these findings clearly illustrate that phagocytes express specific mechanisms that control cytosolic proliferation of *Francisella*. In addition to the effect of IFN- γ on *Francisella* intracellular growth, alternative activation of macrophages by mast cells via interleukin-4 (IL-4) controls intramacrophage growth of LVS (Ketavarapu et al. 2008). Although increased ATP production, prolonged FCP acidification, and up-regulation of the MR have been invoked in this control (Rodriguez et al. 2010), whether IL-4 affects *Francisella* phagosomal escape and/or cytosolic replication remains to be examined in more depth.

Francisella AND INNATE IMMUNE RECOGNITION

Francisella phagocytosis by macrophages and intracellular trafficking through vacuolar and cytosolic compartments likely subjects the bacterium to innate immune recognition by various pattern recognition receptors (PRRs) either located on the cell surface or endosomes, such as the Toll-like receptor (TLRs), or in the cytosolic compartment such as Nod-like receptors (NLRs). TLRs or NLRs typically recognize pathogen-associated molecular patterns (PAMPs) or danger-associated molecular patterns (DAMPs) to trigger proinflammatory responses, among which the activation of the inflammasome, a cytosolic molecular complex, orchestrates caspase-1 activation, processing and release of the proinflammatory cytokines IL-1 β and IL-18, and cell death via pyroptosis.

Because of the unique structure of its lipid A moiety (Hajjar et al. 2006), *Francisella* LPS shows very low endotoxicity and the bacterium does not induce TLR4-mediated signaling. Instead, LVS significantly stimulates TLR2-mediated signaling resulting in proinflammatory cytokine production (Katz et al. 2006; Cole et al. 2007), although it is also capable of subsequently suppressing TLR-mediated signaling and secretion of proinflammatory cytokines induced by other agonists (Telepnev et al. 2003). This ability of *Francisella* to suppress or dampen proinflammatory responses has been extended to the virulent subspecies *tularensis* in human dendritic cells, where infection impairs their activation and function (Bosio and Dow 2005; Chase et al. 2009), further supporting the notion that *Francisella* interferes with immune detection and responses.

INFLAMMASOME ACTIVATION

Given its cytosolic location, *Francisella* has become a model pathogen to study the function of inflammasomes, which has also expanded our understanding of how this bacterium may interfere with immune recognition. Release of *F. novicida* in the macrophage cytosol is sensed in a type I IFN-dependent manner (Henry et al.

2007), and activates the absent in melanoma 2 (AIM2)-containing inflammasome (Fernandes-Alnemri et al. 2010; Rathinam et al. 2010; Jones et al. 2011), a type I IFN-inducible complex whose activation induces secretion of the proinflammatory cytokines IL1 β and pro-IL18 and pyroptosis (Mariathasan et al. 2005). AIM2 inflammasome activation is potentiated by TLR2 signaling (Jones et al. 2010) and is required in vivo in mice to control bacterial burden by eliminating infected macrophages that constitute the *Francisella* proliferation niche (Mariathasan et al. 2005; Fernandes-Alnemri et al. 2010; Jones et al. 2011). Consistent with AIM2 recognizing cytosolic double-stranded DNA (Rathinam et al. 2010), *F. novicida* activation of the AIM2 inflammasome is associated with bacterial release of DNA through lysis in the cytosol (Jones et al. 2011). These studies have focused on murine systems and the nonhuman pathogenic *F. novicida* species, so an important question that remains unanswered is whether the conclusions drawn from these studies also apply to humans and virulent strains. For example, recent evidence indicates that infection of human cells with *F. novicida*, LVS, and the highly virulent *F. tularensis* Schu S4 strains activate the NLRP3 inflammasome in addition to the AIM2 inflammasome (Atianand et al. 2011), suggesting some functional differences in the innate immune complexes involved in *Francisella* recognition between mice and humans. Moreover, several studies using *F. tularensis* subspecies suggest that infections of BMMs with the LVS strain (Huang et al. 2010; Ulland et al. 2010), or of human primary macrophages with virulent Schu S4 (Lindemann et al. 2010) do induce little cytotoxicity compared with *F. novicida*, raising the question of relevance of cytotoxicity in infections with virulent *tularensis* strains.

Given the high adaptation of *Francisella* to the cytosol and the potential of proinflammatory pathways to restrict its proliferation, this bacterium has likely evolved mechanisms to counteract inflammasome activation to preserve its replication niche. In support of this concept, many laboratories have identified hypercytotoxic mutants of *F. novicida* (Brotcke et al. 2006; Hager et al. 2006; Weiss et al. 2007; Lai

J. Celli and T.C. Zahrt

et al. 2010), LVS (Huang et al. 2010; Ulland et al. 2010), and Schu S4 (Lindemann et al. 2010), which typically induced increased inflammasome-dependent cell death and secretion of proinflammatory cytokines in either mouse or human macrophages. Intriguingly, the hypercytotoxic phenotype results from the interruption of genes encoding a variety of proteins, such as the oligopeptide permease OppB (Brotcke et al. 2006), the metallopeptidase PepO (Brotcke et al. 2006; Hager et al. 2006), the inner membrane protein RipA (Huang et al. 2010), the IclR family transcriptional factor FTT0784 and an unknown protein FTT0584 (Weiss et al. 2007), and several proteins involved in biosynthesis of type IV pili, the LPS and the O-antigen polysaccharidic capsule (Huang et al. 2010; Ulland et al. 2010), bringing some confusion as to whether *Francisella* specifically suppress inflammasome activation. The hypothesis of *Francisella* evasion of inflammasome activation was recently challenged by Peng et al., who showed that many previously identified hypercytotoxic mutants of *F. novicida* and LVS are deficient in membrane-associated proteins and lyse more extensively in the cytosol than wild-type bacteria, consequently triggering increased inflammasome activation, secretion of proinflammatory cytokines, and pyroptosis (Peng et al. 2011). Although this study does not completely rule out the existence of *Francisella* inflammasome suppression factors, it elegantly argues that most genes identified as potential suppressors of inflammasome activation do not act specifically and that the hypercytotoxic phenotype is in many cases an indirect consequence of bacterial cell wall fragilization and enhanced release of PAMPs. Because this study has been performed in *F. novicida* and LVS, it will also be interesting to verify that these conclusions also apply to virulent strains.

XENOPHAGIC CAPTURE

Another intracellular innate immune defense mechanism is xenophagy, a selective process of capture of intracellular microorganisms within a double-membrane-bound vacuole, the autophagosome, for delivery to and degradation into the lysosomal compartment (Levine et al. 2011).

Francisella cytosolic location makes this pathogen an ideal substrate for selective autophagic recognition and capture, a process that shares many molecular machineries with nonselective, canonical autophagy. Yet, surprisingly, this bacterium is able to replicate within murine and human macrophages over long periods of time (>18 h) without evidence of a xenophagic response, suggesting it is either capable of avoiding recognition or inhibiting autophagic processes. A belated autophagic response has nonetheless been observed in murine BMMs that encloses a fraction of cytosolic *Francisella* into large vacuoles with autophagic features (Checroun et al. 2006), but the role of these vacuoles and their relevance is unclear, as they do not form in human macrophages (Akimana et al. 2010; Edwards et al. 2010) and may not constitute a bona fide stage of the bacterium's intracellular cycle. Current evidence that *Francisella* may interfere with the autophagy pathway stems from the down-regulation of several autophagy-related genes, such as *beclin1*, *ATG5*, *ATG12*, *ATG16L*, *ATG7*, and *ATG4a* in either Schu S4- or *F. novicida*-infected human monocytes (Butchar et al. 2008; Cremer et al. 2009), which suggests that *Francisella* may suppress an autophagic response at the gene expression level. Yet, it remains to be shown whether down-regulation of some autophagy gene during infection is sufficient to block this constitutive pathway rapidly enough to prevent bacteria that have reached the cytosol from being targeted. Interestingly, a $\Delta dipA$ (FTT0369c) deletion mutant of SchuS4, which is deficient in cytosolic replication, is eventually captured and cleared by autophagy following a loss of viability in the cytosol (Chong et al. 2012), suggesting that viable *Francisella* may possess mechanisms that prevent their recognition by the autophagic machinery. Additionally, whether *Francisella* infection negatively modulates nonselective autophagy also needs to be examined to further understand *Francisella* potential interference with this degradative pathway.

CONCLUDING REMARKS

The ability of *Francisella* to survive and replicate within phagocytes and other host cells follow-

ing infection is a key aspect of its life cycle and represents an essential step required by this bacterium to cause disease within the host. Alterations in mechanisms that mediate this ability, including the engagement of appropriate receptors, resistance to ROS, escape from the phagosome, replication within the cytosol, and/or avoidance of innate immune recognition or other defense mechanisms, can lead to altered survival characteristics and potential attenuation of *F. tularensis* in virulence in vitro and/or in vivo. Continued study of the genetic determinants contributing to these mechanisms will be essential for the development of therapeutics or vaccines that are able to specifically inhibit or prevent disease caused by this bacterium.

ACKNOWLEDGMENTS

The authors apologize to those investigators in the field whose excellent work we were not able to reference. We are grateful to Anita Mora at the Rocky Mountain Laboratory for her assistance with graphic art. T.C.Z. acknowledges support from the National Institutes of Health, National Institute of Allergy and Infectious Diseases (NIAID) (1R21 AI097597-01A1), and the NIAID's Regional Center of Excellence for Bio-defense and Emerging Infectious Diseases Research Program. Membership within and support from the Region V Great Lakes Regional Center of Excellence (National Institutes of Health Award 2-U54-AI-057153) is also acknowledged. J.C. acknowledges support from the Intramural Research Program of the National Institutes of Health, National Institute of Allergy and Infectious Diseases.

REFERENCES

- Akimana C, Al-Khodori S, Abu Kwaik Y. 2010. Host factors required for modulation of phagosome biogenesis and proliferation of *Francisella tularensis* within the cytosol. *PLoS ONE* 5: e11025.
- Alkhuder K, Meibom KL, Dubail I, Dupuis M, Charbit A. 2009. Glutathione provides a source of cysteine essential for intracellular multiplication of *Francisella tularensis*. *PLoS Pathog* 5: e1000284.
- Allen LA, McCaffrey RL. 2007. To activate or not to activate: Distinct strategies used by *Helicobacter pylori* and *Francisella tularensis* to modulate the NADPH oxidase and survive in human neutrophils. *Immunol Rev* 219: 103–117.
- Anthony LD, Burke RD, Nano FE. 1991. Growth of *Francisella* spp. in rodent macrophages. *Infect Immun* 59: 3291–3296.
- Anthony LS, Morrissey PJ, Nano FE. 1992. Growth inhibition of *Francisella tularensis* live vaccine strain by IFN- γ -activated macrophages is mediated by reactive nitrogen intermediates derived from L-arginine metabolism. *J Immunol* 148: 1829–1834.
- Atianand MK, Duffy EB, Shah A, Kar S, Malik M, Harton JA. 2011. *Francisella tularensis* reveals a disparity between human and mouse NLRP3 inflammasome activation. *J Biol Chem* 286: 39033–39042.
- Babior BM. 2004. NADPH oxidase. *Curr Opin Immunol* 16: 42–47.
- Bakshi CS, Malik M, Regan K, Melendez JA, Metzger DW, Pavlov VM, Sellati TJ. 2006. Superoxide dismutase B gene (sodB)-deficient mutants of *Francisella tularensis* demonstrate hypersensitivity to oxidative stress and attenuated virulence. *J Bacteriol* 188: 6443–6448.
- Balogopal A, MacFarlane AS, Mohapatra N, Soni S, Gunn JS, Schlesinger LS. 2006. Characterization of the receptor-ligand pathways important for entry and survival of *Francisella tularensis* in human macrophages. *Infect Immun* 74: 5114–5125.
- Barel M, Hovanessian AG, Meibom K, Briand JP, Dupuis M, Charbit A. 2008. A novel receptor-ligand pathway for entry of *Francisella tularensis* in monocyte-like THP-1 cells: Interaction between surface nucleolin and bacterial elongation factor Tu. *BMC Microbiol* 8: 145.
- Barker JH, McCaffrey RL, Baman NK, Allen LA, Weiss JP, Nauseef WM. 2009a. The role of complement opsonization in interactions between *F. tularensis* subsp. novicida and human neutrophils. *Microbes Infect* 11: 762–769.
- Barker JR, Chong A, Wehrly TD, Yu JJ, Rodriguez SA, Liu J, Celli J, Arulanandam BP, Klose KE. 2009b. The *Francisella tularensis* pathogenicity island encodes a secretion system that is required for phagosome escape and virulence. *Mol Microbiol* 74: 1459–1470.
- Baron GS, Nano FE. 1998. MglA and MglB are required for the intramacrophage growth of *Francisella novicida*. *Mol Microbiol* 29: 247–259.
- Ben Nasr A, Haithcoat J, Masterson JE, Gunn JS, Eaves-Pyles T, Klimpel GR. 2006. Critical role for serum opsonins and complement receptors CR3 (CD11b/CD18) and CR4 (CD11c/CD18) in phagocytosis of *Francisella tularensis* by human dendritic cells (DC): Uptake of *Francisella* leads to activation of immature DC and intracellular survival of the bacteria. *J Leukoc Biol* 80: 774–786.
- Bonquist L, Lindgren H, Golovliov I, Guina T, Sjostedt A. 2008. MglA and Igl proteins contribute to the modulation of *Francisella tularensis* live vaccine strain-containing phagosomes in murine macrophages. *Infect Immun* 76: 3502–3510.
- Bosio CM, Dow SW. 2005. *Francisella tularensis* induces aberrant activation of pulmonary dendritic cells. *J Immunol* 175: 6792–6801.
- Broms JE, Meyer L, Lavander M, Larsson P, Sjostedt A. 2012. DotU and VgrG, core components of type VI secretion

J. Celli and T.C. Zahrt

- systems, are essential for *Francisella* LVS pathogenicity. *PLoS ONE* **7**: e34639.
- Brotcke A, Monack DM. 2008. Identification of fevR, a novel regulator of virulence gene expression in *Francisella novicida*. *Infect Immun* **76**: 3473–3480.
- Brotcke A, Weiss DS, Kim CC, Chain P, Malfatti S, Garcia E, Monack DM. 2006. Identification of MglA-regulated genes reveals novel virulence factors in *Francisella tularensis*. *Infect Immun* **74**: 6642–6655.
- Buchan BW, McCaffrey RL, Lindemann SR, Allen LA, Jones BD. 2009. Identification of migR, a regulatory element of the *Francisella tularensis* live vaccine strain iglABCD virulence operon required for normal replication and trafficking in macrophages. *Infect Immun* **77**: 2517–2529.
- Butchar JP, Cremer TJ, Clay CD, Gavrilin MA, Wewers MD, Marsh CB, Schlesinger LS, Tridandapani S. 2008. Microarray analysis of human monocytes infected with *Francisella tularensis* identifies new targets of host response subversion. *PLoS ONE* **3**: e2924.
- Chase JC, Celli J, Bosio CM. 2009. Direct and indirect impairment of human dendritic cell function by virulent *Francisella tularensis* Schu S4. *Infect Immun* **77**: 180–195.
- Checroun C, Wehrly TD, Fischer ER, Hayes SF, Celli J. 2006. Autophagy-mediated reentry of *Francisella tularensis* into the endocytic compartment after cytoplasmic replication. *Proc Natl Acad Sci* **103**: 14578–14583.
- Child R, Wehrly TD, Rockx-Brouwer D, Dorward DW, Celli J. 2010. Acid phosphatases do not contribute to the pathogenesis of type A *Francisella tularensis*. *Infect Immun* **78**: 59–67.
- Chong A, Wehrly TD, Nair V, Fischer ER, Barker JR, Klose KE, Celli J. 2008. The early phagosomal stage of *Francisella tularensis* determines optimal phagosomal escape and *Francisella* pathogenicity island protein expression. *Infect Immun* **76**: 5488–5499.
- Chong A, Wehrly TD, Child R, Hansen B, Hwang S, Virgin HW, Celli J. 2012. Cytosolic clearance of replication-deficient mutants reveals *Francisella tularensis* interactions with the autophagic pathway. *Autophagy* **8**: 1342–1356.
- Clemens DL, Lee BY, Horwitz MA. 2004. Virulent and avirulent strains of *Francisella tularensis* prevent acidification and maturation of their phagosomes and escape into the cytoplasm in human macrophages. *Infect Immun* **72**: 3204–3217.
- Clemens DL, Lee BY, Horwitz MA. 2005. *Francisella tularensis* enters macrophages via a novel process involving pseudopod loops. *Infect Immun* **73**: 5892–5902.
- Clemens DL, Lee BY, Horwitz MA. 2009. *Francisella tularensis* phagosomal escape does not require acidification of the phagosome. *Infect Immun* **77**: 1757–1773.
- Cole LE, Shirey KA, Barry E, Santiago A, Rallabhandi P, Elkins KL, Puche AC, Michalek SM, Vogel SN. 2007. Toll-like receptor 2-mediated signaling requirements for *Francisella tularensis* live vaccine strain infection of murine macrophages. *Infect Immun* **75**: 4127–4137.
- Cremer TJ, Amer A, Tridandapani S, Butchar JP. 2009. *Francisella tularensis* regulates autophagy-related host cell signaling pathways. *Autophagy* **5**: 125–128.
- Dai S, Mohapatra NP, Schlesinger LS, Gunn JS. 2011. The acid phosphatase AcpA is secreted in vitro and in macrophages by *Francisella* spp. *Infect Immun* **80**: 1088–1097.
- Dienst Jr. FTJr. 1963. Tularemia: A perusal of three hundred thirty-nine cases. *J La State Med Soc* **115**: 114–127.
- Edwards JA, Rockx-Brouwer D, Nair V, Celli J. 2010. Restricted cytosolic growth of *Francisella tularensis* subsp. *tularensis* by IFN- γ activation of macrophages. *Microbiology* **156**: 327–339.
- Elkins KL, Rhinehart-Jones TR, Culkin SJ, Yee D, Winegar RK. 1996. Minimal requirements for murine resistance to infection with *Francisella tularensis* LVS. *Infect Immun* **64**: 3288–3293.
- Fernandes-Alnemri T, Yu JW, Juliana C, Solorzano L, Kang S, Wu J, Datta P, McCormick M, Huang L, McDermott E, et al. 2010. The AIM2 inflammasome is critical for innate immunity to *Francisella tularensis*. *Nat Immunol* **11**: 385–393.
- Forestal CA, Malik M, Catlett SV, Savitt AG, Benach JL, Sellati TJ, Furie MB. 2007. *Francisella tularensis* has a significant extracellular phase in infected mice. *J Infect Dis* **196**: 134–137.
- Fortier AH, Polsinelli T, Green SJ, Nacy CA. 1992. Activation of macrophages for destruction of *Francisella tularensis*: Identification of cytokines, effector cells, and effector molecules. *Infect Immun* **60**: 817–825.
- Fuller JR, Craven RR, Hall JD, Kijek TM, Taft-Benz S, Kawula TH. 2008. RipA, a cytoplasmic membrane protein conserved among *Francisella* species, is required for intracellular survival. *Infect Immun* **76**: 4934–4943.
- Geier H, Celli J. 2011. Phagocytic receptors dictate phagosomal escape and intracellular proliferation of *Francisella tularensis*. *Infect Immun* **79**: 2204–2214.
- Golovliov I, Baranov V, Krocova Z, Kovarova H, Sjostedt A. 2003. An attenuated strain of the facultative intracellular bacterium *Francisella tularensis* can escape the phagosome of monocytic cells. *Infect Immun* **71**: 5940–5950.
- Hager AJ, Bolton DL, Pelletier MR, Brittnacher MJ, Gallagher LA, Kaul R, Skerrett SJ, Miller SI, Guina T. 2006. Type IV pili-mediated secretion modulates *Francisella* virulence. *Mol Microbiol* **62**: 227–237.
- Hajjar AM, Harvey MD, Shaffer SA, Goodlett DR, Sjostedt A, Edebro H, Forsman M, Bystrom M, Pelletier M, Wilson CB, et al. 2006. Lack of in vitro and in vivo recognition of *Francisella tularensis* subspecies lipopolysaccharide by Toll-like receptors. *Infect Immun* **74**: 6730–6738.
- Hall JD, Craven RR, Fuller JR, Pickles RJ, Kawula TH. 2007. *Francisella tularensis* replicates within alveolar type II epithelial cells in vitro and in vivo following inhalation. *Infect Immun* **75**: 1034–1039.
- Hall JD, Woolard MD, Gunn BM, Craven RR, Taft-Benz S, Frelinger JA, Kawula TH. 2008. Infected-host-cell repertoire and cellular response in the lung following inhalation of *Francisella tularensis* Schu S4, LVS, or U112. *Infect Immun* **76**: 5843–5852.
- Henry T, Brotcke A, Weiss DS, Thompson LJ, Monack DM. 2007. Type I interferon signaling is required for activation of the inflammasome during *Francisella* infection. *J Exp Med* **204**: 987–994.

- Huang MT, Mortensen BL, Taxman DJ, Craven RR, Taft-Benz S, Kijek TM, Fuller JR, Davis BK, Allen IC, Brickley WJ, et al. 2010. Deletion of *ripA* alleviates suppression of the inflammasome and MAPK by *Francisella tularensis*. *J Immunol* **185**: 5476–5485.
- Huynh KK, Grinstein S. 2007. Regulation of vacuolar pH and its modulation by some microbial species. *Microbiol Mol Biol Rev* **71**: 452–462.
- Jones JW, Kayagaki N, Broz P, Henry T, Newton K, O'Rourke K, Chan S, Dong J, Qu Y, Roose-Girma M, et al. 2010. Absent in melanoma 2 is required for innate immune recognition of *Francisella tularensis*. *Proc Natl Acad Sci* **107**: 9771–9776.
- Jones JW, Broz P, Monack DM. 2011. Innate immune recognition of *Francisella tularensis*: Activation of type-I interferons and the inflammasome. *Front Microbiol* **2**: 16.
- Katz J, Zhang P, Martin M, Vogel SN, Michalek SM. 2006. Toll-like receptor 2 is required for inflammatory responses to *Francisella tularensis* LVS. *Infect Immun* **74**: 2809–2816.
- Ketavarapu JM, Rodriguez AR, Yu JJ, Cong Y, Murthy AK, Forsthuber TG, Guentzel MN, Klose KE, Berton MT, Arulanandam BP. 2008. Mast cells inhibit intramacrophage *Francisella tularensis* replication via contact and secreted products including IL-4. *Proc Natl Acad Sci* **105**: 9313–9318.
- KuoLee R, Harris G, Conlan JW, Chen W. 2011. Role of neutrophils and NADPH phagocyte oxidase in host defense against respiratory infection with virulent *Francisella tularensis* in mice. *Microbes Infect* **13**: 447–456.
- Lai XH, Shirley RL, Crosa L, Kanistanon D, Tempel R, Ernst RK, Gallagher LA, Manoil C, Heffron F. 2010. Mutations of *Francisella novicida* that alter the mechanism of its phagocytosis by murine macrophages. *PLoS ONE* **5**: e11857.
- Larsson P, Oyston PC, Chain P, Chu MC, Duffield M, Fuxelius HH, Garcia E, Halltorp G, Johansson D, Isherwood KE, et al. 2005. The complete genome sequence of *Francisella tularensis*, the causative agent of tularemia. *Nat Genet* **37**: 153–159.
- Leiby DA, Fortier AH, Crawford RM, Schreiber RD, Nacy CA. 1992. In vivo modulation of the murine immune response to *Francisella tularensis* LVS by administration of anticytokine antibodies. *Infect Immun* **60**: 84–89.
- Levine B, Mizushima N, Virgin HW. 2011. Autophagy in immunity and inflammation. *Nature* **469**: 323–335.
- Lindemann SR, Peng K, Long ME, Hunt JR, Apicella MA, Monack DM, Allen LA, Jones BD. 2010. *Francisella tularensis* Schu S4 O-antigen and capsule biosynthesis gene mutants induce early cell death in human macrophages. *Infect Immun* **79**: 581–594.
- Lindgren H, Golovliov I, Baranov V, Ernst RK, Telepnev M, Sjostedt A. 2004. Factors affecting the escape of *Francisella tularensis* from the phagolysosome. *J Med Microbiol* **53**: 953–958.
- Lindgren H, Stenman L, Tarnvik A, Sjostedt A. 2005. The contribution of reactive nitrogen and oxygen species to the killing of *Francisella tularensis* LVS by murine macrophages. *Microbes Infect* **7**: 467–475.
- Lindgren H, Shen H, Zingmark C, Golovliov I, Conlan W, Sjostedt A. 2007. Resistance of *Francisella tularensis* strains against reactive nitrogen and oxygen species with special reference to the role of KatG. *Infect Immun* **75**: 1303–1309.
- Llewellyn AC, Jones CL, Napier BA, Bina JE, Weiss DS. 2011. Macrophage replication screen identifies a novel *Francisella* hydroperoxide resistance protein involved in virulence. *PLoS ONE* **6**: e24201.
- Mariathasan S, Weiss DS, Dixit VM, Monack DM. 2005. Innate immunity against *Francisella tularensis* is dependent on the ASC/caspase-1 axis. *J Exp Med* **202**: 1043–1049.
- McCaffrey RL, Allen LA. 2006. *Francisella tularensis* LVS evades killing by human neutrophils via inhibition of the respiratory burst and phagosome escape. *J Leukoc Biol* **80**: 1224–1230.
- McCaffrey RL, Schwartz JT, Lindemann SR, Moreland JG, Buchan BW, Jones BD, Allen LA. 2010. Multiple mechanisms of NADPH oxidase inhibition by type A and type B *Francisella tularensis*. *J Leukoc Biol* **88**: 791–805.
- McRae S, Pagliai FA, Mohapatra NP, Gener A, Mahmou AS, Gunn JS, Lorca GL, Gonzalez CF. 2009. Inhibition of AcpA phosphatase activity with ascorbate attenuates *Francisella tularensis* intramacrophage survival. *J Biol Chem* **285**: 5171–5177.
- Meibom KL, Barel M, Charbit A. 2009. Loops and networks in control of *Francisella tularensis* virulence. *Future Microbiol* **4**: 713–729.
- Melillo AA, Mahawar M, Sellati TJ, Malik M, Metzger DW, Melendez JA, Bakshi CS. 2009. Identification of *Francisella tularensis* live vaccine strain CuZn superoxide dismutase as critical for resistance to extracellularly generated reactive oxygen species. *J Bacteriol* **191**: 6447–6456.
- Mohapatra NP, Balagopal A, Soni S, Schlesinger LS, Gunn JS. 2007. AcpA is a *Francisella* acid phosphatase that affects intramacrophage survival and virulence. *Infect Immun* **75**: 390–396.
- Mohapatra NP, Soni S, Reilly TJ, Liu J, Klose KE, Gunn JS. 2008. Combined deletion of four *Francisella novicida* acid phosphatases attenuates virulence and macrophage vacuolar escape. *Infect Immun* **76**: 3690–3699.
- Mohapatra NP, Soni S, Rajaram MV, Dang PM, Reilly TJ, El-Benna J, Clay CD, Schlesinger LS, Gunn JS. 2010. *Francisella* acid phosphatases inactivate the NADPH oxidase in human phagocytes. *J Immunol* **184**: 5141–5150.
- Nano FE, Zhang N, Cowley SC, Klose KE, Cheung KK, Roberts MJ, Ludu JS, Letendre GW, Meierovics AI, Stephens G, et al. 2004. A *Francisella tularensis* pathogenicity island required for intramacrophage growth. *J Bacteriol* **186**: 6430–6436.
- O'Riordan M, Portnoy DA. 2002. The host cytosol: Front-line or home front? *Trends Microbiol* **10**: 361–364.
- Oyston PC, Sjostedt A, Titball RW. 2004. Tularemia: Bio-terrorism defence renews interest in *Francisella tularensis*. *Nat Rev Microbiol* **2**: 967–978.
- Pechous R, Celli J, Penoske R, Hayes SE, Frank DW, Zahrt TC. 2006. Construction and characterization of an attenuated purine auxotroph in a *Francisella tularensis* live vaccine strain. *Infect Immun* **74**: 4452–4461.
- Pechous RD, McCarthy TR, Mohapatra NP, Soni S, Penoske RM, Salzman NH, Frank DW, Gunn JS, Zahrt TC. 2008. A *Francisella tularensis* Schu S4 purine auxo-

J. Celli and T.C. Zahrt

- troph is highly attenuated in mice but offers limited protection against homologous intranasal challenge. *PLoS ONE* **3**: e2487.
- Peng K, Broz P, Jones J, Joubert LM, Monack D. 2011. Elevated AIM2-mediated pyroptosis triggered by hypercytotoxic *Francisella* mutant strains is attributed to increased intracellular bacteriolysis. *Cell Microbiol* **13**: 1586–1600.
- Pierini LM. 2006. Uptake of serum-opsonized *Francisella tularensis* by macrophages can be mediated by class A scavenger receptors. *Cell Microbiol* **8**: 1361–1370.
- Polsinelli T, Meltzer MS, Fortier AH. 1994. Nitric oxide-independent killing of *Francisella tularensis* by IFN- γ -stimulated murine alveolar macrophages. *J Immunol* **153**: 1238–1245.
- Qin A, Mann BJ. 2006. Identification of transposon insertion mutants of *Francisella tularensis* strain Schu S4 deficient in intracellular replication in the hepatic cell line HepG2. *BMC Microbiol* **6**: 69.
- Qin A, Scott DW, Thompson JA, Mann BJ. 2009. Identification of an essential *Francisella tularensis* subsp. *tularensis* virulence factor. *Infect Immun* **77**: 152–161.
- Rathinam VA, Jiang Z, Waggoner SN, Sharma S, Cole LE, Waggoner L, Vanaja SK, Monks BG, Ganesan S, Latz E, et al. 2010. The AIM2 inflammasome is essential for host defense against cytosolic bacteria and DNA viruses. *Nat Immunol* **11**: 395–402.
- Reilly TJ, Baron GS, Nano FE, Kuhlenschmidt MS. 1996. Characterization and sequencing of a respiratory burst-inhibiting acid phosphatase from *Francisella tularensis*. *J Biol Chem* **271**: 10973–10983.
- Rodriguez AR, Yu JJ, Murthy AK, Guentzel MN, Klose KE, Forsthuber TG, Chambers JP, Berton MT, Arulanandam BP. 2010. Mast cell/IL-4 control of *Francisella tularensis* replication and host cell death is associated with increased ATP production and phagosomal acidification. *Mucosal Immunol* **4**: 217–226.
- Santic M, Molmeret M, Abu Kwaik Y. 2005a. Modulation of biogenesis of the *Francisella tularensis* subsp. *novicida*-containing phagosome in quiescent human macrophages and its maturation into a phagolysosome upon activation by IFN- γ . *Cell Microbiol* **7**: 957–967.
- Santic M, Molmeret M, Klose KE, Jones S, Kwaik YA. 2005b. The *Francisella tularensis* pathogenicity island protein IgIC and its regulator MglA are essential for modulating phagosome biogenesis and subsequent bacterial escape into the cytoplasm. *Cell Microbiol* **7**: 969–979.
- Santic M, Asare R, Skrobonja I, Jones S, Abu Kwaik Y. 2008. Acquisition of the vacuolar ATPase proton pump and phagosome acidification are essential for escape of *Francisella tularensis* into the macrophage cytosol. *Infect Immun* **76**: 2671–2677.
- Saslaw S, Eigelsbach HT, Prior JA, Wilson HE, Carhart S. 1961a. Tularemia vaccine study. II. Respiratory challenge. *Arch Intern Med* **107**: 702–714.
- Saslaw S, Eigelsbach HT, Wilson HE, Prior JA, Carhart S. 1961b. Tularemia vaccine study. I. Intracutaneous challenge. *Arch Intern Med* **107**: 689–701.
- Schmerk CL, Duplantis BN, Howard PL, Nano FE. 2009. A *Francisella novicida* pdpA mutant exhibits limited intracellular replication and remains associated with the lysosomal marker LAMP-1. *Microbiology* **155**: 1498–1504.
- Schulert GS, Allen LA. 2006. Differential infection of mononuclear phagocytes by *Francisella tularensis*: Role of the macrophage mannose receptor. *J Leukoc Biol* **80**: 563–571.
- Schulert GS, McCaffrey RL, Buchan BW, Lindemann SR, Hollenback C, Jones BD, Allen LA. 2009. *Francisella tularensis* genes required for inhibition of the neutrophil respiratory burst and intramacrophage growth identified by random transposon mutagenesis of strain LVS. *Infect Immun* **77**: 1324–1336.
- Su J, Yang J, Zhao D, Kawula TH, Banas JA, Zhang JR. 2007. Genome-wide identification of *Francisella tularensis* virulence determinants. *Infect Immun* **75**: 3089–3101.
- Telepnev M, Golovliov I, Grundstrom T, Tarnvik A, Sjoestedt A. 2003. *Francisella tularensis* inhibits Toll-like receptor-mediated activation of intracellular signalling and secretion of TNF- α and IL-1 from murine macrophages. *Cell Microbiol* **5**: 41–51.
- Tempel R, Lai XH, Crosa L, Kozlowski B, Heffron F. 2006. Attenuated *Francisella novicida* transposon mutants protect mice against wild-type challenge. *Infect Immun* **74**: 5095–5105.
- Ulland TK, Buchan BW, Ketterer MR, Fernandes-Alnemri T, Meyerholz DK, Apicella MA, Alnemri ES, Jones BD, Nauseef WM, Sutterwala FS. 2010. Cutting edge: Mutation of *Francisella tularensis* mviN leads to increased macrophage absent in melanoma 2 inflammasome activation and a loss of virulence. *J Immunol* **185**: 2670–2674.
- Wehrly TD, Chong A, Virtaneva K, Sturdevant DE, Child R, Edwards JA, Brouwer D, Nair V, Fischer ER, Wicke L, et al. 2009. Intracellular biology and virulence determinants of *Francisella tularensis* revealed by transcriptional profiling inside macrophages. *Cell Microbiol* **11**: 1128–1150.
- Weiss DS, Brotcke A, Henry T, Margolis JJ, Chan K, Monack DM. 2007. In vivo negative selection screen identifies genes required for *Francisella* virulence. *Proc Natl Acad Sci* **104**: 6037–6042.
- Zahrt TC, Deretic V. 2002. Reactive nitrogen and oxygen intermediates and bacterial defenses: Unusual adaptations in *Mycobacterium tuberculosis*. *Antioxid Redox Signal* **4**: 141–159.

Cold Spring Harbor Perspectives in Medicine

Mechanisms of *Francisella tularensis* Intracellular Pathogenesis

Jean Celli and Thomas C. Zahrt

Cold Spring Harb Perspect Med 2013; doi: 10.1101/cshperspect.a010314

Subject Collection [Bacterial Pathogenesis](#)

Therapeutic and Prophylactic Applications of Bacteriophage Components in Modern Medicine

Sankar Adhya, Carl R. Merrill and Biswajit Biswas

Vaccines, Reverse Vaccinology, and Bacterial Pathogenesis

Isabel Delany, Rino Rappuoli and Kate L. Seib

***Helicobacter* and *Salmonella* Persistent Infection Strategies**

Denise M. Monack

Echoes of a Distant Past: The *cag* Pathogenicity Island of *Helicobacter pylori*

Nicola Pacchiani, Stefano Censini, Ludovico Buti, et al.

RNA-Mediated Regulation in Pathogenic Bacteria

Isabelle Caldelari, Yanjie Chao, Pascale Romby, et al.

The Pneumococcus: Epidemiology, Microbiology, and Pathogenesis

Birgitta Henriques-Normark and Elaine I. Tuomanen

Pathogenesis of Meningococcemia

Mathieu Coureuil, Olivier Join-Lambert, Hervé Lécuyer, et al.

Chlamydial Intracellular Survival Strategies

Robert J. Bastidas, Cherylyn A. Elwell, Joanne N. Engel, et al.

Mechanisms and Biological Roles of Contact-Dependent Growth Inhibition Systems

Christopher S. Hayes, Sanna Koskiniemi, Zachary C. Ruhe, et al.

A Genome-Wide Perspective of Human Diversity and Its Implications in Infectious Disease

Jérémy Manry and Lluís Quintana-Murci

Host Specificity of Bacterial Pathogens

Andreas Bäumlér and Ferric C. Fang

The Inside Story of *Shigella* Invasion of Intestinal Epithelial Cells

Nathalie Carayol and Guy Tran Van Nhieu

***Bartonella* and *Brucella*—Weapons and Strategies for Stealth Attack**

Houchaima Ben-Tekaya, Jean-Pierre Gorvel and Christoph Dehio

Concepts and Mechanisms: Crossing Host Barriers

Kelly S. Doran, Anirban Banerjee, Olivier Disson, et al.

Genome Dynamics in *Legionella*: The Basis of Versatility and Adaptation to Intracellular Replication

Laura Gomez-Valero and Carmen Buchrieser

Mechanisms of *Francisella tularensis* Intracellular Pathogenesis

Jean Celli and Thomas C. Zahrt

For additional articles in this collection, see <http://perspectivesinmedicine.cshlp.org/cgi/collection/>